OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
23
Results
Show all
Save search
Copy query
Show results for
Unknown
(23)
Publication Date
Release Date
2021
(10)
2023
(4)
2022
(4)
2020
(2)
2025
(1)
2024
(1)
2016
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Biomarker Panel for Chronic Graft-Versus-Host Disease.
Not available
S-EPMC5012688
|
biostudies-literature
Cite
Whole-genome sequencing of a sporadic primary immunodeficiency cohort.
Not available
S-EPMC7334047
|
biostudies-literature
Cite
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Not available
S-EPMC8362594
|
biostudies-literature
Cite
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
Not available
S-EPMC7953461
|
biostudies-literature
Cite
A second update on mapping the human genetic architecture of COVID-19.
Not available
S-EPMC10482689
|
biostudies-literature
Cite
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483
|
biostudies-literature
Cite
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8598213
|
biostudies-literature
Cite
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355
|
biostudies-literature
Cite
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC7884931
|
biostudies-literature
Cite
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets